Comparative Pharmacology
Head-to-head clinical analysis: LITHOBID versus LITHONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LITHOBID versus LITHONATE.
LITHOBID vs LITHONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium modulates neurotransmitter receptors and second messenger systems; inhibits inositol monophosphatase, reducing phosphoinositide signaling; alters ion transport; enhances serotonin and norepinephrine reuptake; modulates G-proteins.
Lithium modulates neurotransmitter activity in the central nervous system, including inhibition of inositol monophosphatase, leading to reduced phosphoinositide signaling; alters G-protein coupled receptor signaling; and inhibits glycogen synthase kinase-3 (GSK-3). It also affects ion transport, including sodium and potassium, and stabilizes neuronal excitability.
300-600 mg orally 2-3 times daily; extended-release formulation (LITHOBID) 300-450 mg orally twice daily.
300-600 mg orally 2-3 times daily for acute mania; 600-1200 mg/day in divided doses for maintenance. Titrate to serum lithium level 0.8-1.2 mEq/L (acute) or 0.6-1.2 mEq/L (maintenance).
None Documented
None Documented
Terminal elimination half-life: 18-36 hours (mean 24 hours) in young adults, increases with age and renal impairment. Long half-life supports once-daily dosing in sustained-release formulation.
Terminal elimination half-life 18-36 hours in young adults, up to 48-72 hours in elderly or with renal impairment; steady state reached in 5-7 days.
Renal: >95% excreted unchanged in urine. Biliary/fecal: <5%.
Primarily renal excretion (>95% as unchanged lithium); less than 5% excreted in feces via bile.
Category C
Category C
Mood Stabilizer
Mood Stabilizer